Studies of Neuregulin/ERBB Signaling in Human Heart
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Heart Disease, Vascular Disease, Heart Failure. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells
Overview
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Detailed description
The EGF family of receptor tyrosine kinases (a.k.a. ERBB receptors) mediate the effects of the epidermal growth factor (EGF) family including Neuregulin-1β (NRG). NRG and ERBB1-4 are critical for cardiac development and maintenance of the adult heart. Current understanding of the role of EGF/NRG/ERBB signaling in the cardiovascular system is rapidly evolving due to recent findings in non-myocyte cell populations. This study is examining a population of progenitor cells in the adult human heart that responds to EGF and NRG. Subjects are enrolled who are scheduled to undergo heart surgery and are willing to allow for a small biopsy to be taken from their hearts during surgery. Biopsies are taken to the laboratory where cells are separated and analyzed by flow cytometry and grown in cell culture to understand how their biology is regulated by NRG and EGF.
Primary outcome measures
- The number of highly proliferative clones isolated [Time frame: up to 14 days from isolation]
Secondary outcome measures (1)
- Flow cytometric ERBB receptor expression in highly proliferative clones isolated from heart tissue [Time frame: up to 14 days from isolation]
Eligibility criteria
Inclusion criteria
- Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.
Exclusion criteria
- less than 18 years of age
- unwilling or unable to provide informed consent
- known active myocarditis
- hypertrophic cardiomyopathy
- constrictive pericarditis or other significant pericardial disease
- severe pulmonary hypertension
- significant renal impairment (Cr > 2.5 mg/dL)
- severe ventricular arrhythmias
- pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Maine Medical Center — Portland
Publications
- de Kay JT, Carver J, Shevenell B, Kosta AM, Tsibulnikov S, Certo E, Sawyer DB, Ryzhov S, Robich MP. Decreased expression of ErbB2 on left ventricular epicardial cells in patients with diabetes mellitus. Cell Signal. 2022 Aug;96:110360. doi: 10.1016/j.cellsig.2022.110360. Epub 2022 May 21. PMID 35609807
- Ryzhov S, Robich MP, Roberts DJ, Favreau-Lessard AJ, Peterson SM, Jachimowicz E, Rath R, Vary CPH, Quinn R, Kramer RS, Sawyer DB. ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC). J Mol Cell Cardiol. 2018 Feb;115:39-50. doi: 10.1016/j.yjmcc.2017.12.013. Epub 2017 Dec 29. PMID 29291395
- Robich M, Ryzhov S, Kacer D, Palmeri M, Peterson SM, Quinn RD, Carter D, Sheppard F, Hayes T, Sawyer DB, Rappold J, Prudovsky I, Kramer RS. Prolonged Cardiopulmonary Bypass is Associated With Endothelial Glycocalyx Degradation. J Surg Res. 2020 Jul;251:287-295. doi: 10.1016/j.jss.2020.02.011. Epub 2020 Apr 30. PMID 32199337
Identifiers
NCT: NCT02820233 · 4590